A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies.
一项针对低级别 B 细胞淋巴瘤患者的 I 期临床试验，将 OX40 激动剂添加到原位治疗性癌症疫苗中，凸显了从小鼠研究到人体研究转化过程中面临的挑战
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2770
Shree Tanaya, Czerwinski Debra, Haebe Sarah, Sathe Anuja, Grimes Sue, Martin Brock, Ozawa Michael, Hoppe Richard, Ji Hanlee, Levy Ronald
